Pharmacy Wolverine

REFERENCES · BPC-157 + TB-500

The BPC-157 TB-500 references, every tag traced to its source.

Peer-reviewed studies and reviews for each constituent, plus the FDA pages behind the 503A access status. DOIs and PubMed links throughout.

Back to the researchThe access line

How to read this list

Every citation marked [N] across this site resolves to a numbered entry below. The studies on each constituent of the BPC-157 TB-500 blend are peer-reviewed primary research or reviews; the regulatory entries are FDA pages verified to load and contain the cited content, plus the WADA Prohibited List for anti-doping status.

References 1-12 are the scientific record on the two peptides. References 13-16 are the access and anti-doping sources behind the Wolverine legal status and FDA 503A category. Where a study used animal models, the citation reflects that — none of these entries should be read as human-use evidence for the combination.

  1. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
  2. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. ↗
  3. Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004;23(18):3599-3608. ↗
  4. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. ↗
  5. Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. ↗
  6. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. ↗
  7. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. ↗
  8. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
  9. Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats. Pharmaceutics. 2025;17(1):119. ↗
  10. Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Experimental Lower-Extremity Ischemia-Reperfusion Injury. Medicina (Kaunas). 2025;61(2):291. ↗
  11. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. ↗
  12. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals (Basel). 2024;17(4):461. ↗
  13. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (Category 2 entries for BPC-157 and 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500'; list update effective September 29, 2023). ↗
  14. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (BPC-157 and TB-500 listed as bulk drug substances being considered for inclusion on the 503A Bulks List). ↗
  15. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 1 / Category 2 framework and the 503A/503B compounding pathway). ↗
  16. World Anti-Doping Agency. The Prohibited List (BPC-157 under category S0 Non-Approved Substances; TB-500 / thymosin beta-4 under prohibited peptide and tissue-repair categories). ↗